

**Purpose/Objective(s):** This study aimed to investigate local regional function changes at 3 months after radiotherapy (RT) and their relationship with baseline (pre-RT) and during-RT functional level in patients with non-small cell lung cancer (NSCLC).

**Materials/Methods:** 60 patients with stages I-III NSCLC were eligible for this prospective study. The patients were treated with a definitive course of RT to  $\geq 60\text{Gy}$ ,  $\pm$ chemotherapy. Ventilation and perfusion (V/Q) SPECT-CT were performed pre-, during-, and 3 months Post- RT. The pre-RT SPECT was used to map the lung into three functional regions: FL=functional activity  $> 60\%$  of normal lung; PF= functional activity 30-60% of normal control; and DF=functional activity  $< 30\%$  of normal control. SPECT-CT scans of various time points were registered with simulation CT for dosimetric computation. Paired t-test was applied for statistic assessment,  $p < 0.05$  was considered to be significant.

**Results:** Preliminary results of 15 patients with a minimum follow-up of 24 months are summarized here. On average, regional function reduced by 10-24% 3 months after completion of radiation therapy. Such reduction was significantly correlated (positively) with the functional levels at baseline and changes at 45 Gy during-RT. For example, perfusion function reduced significantly in FL region in 80% (12/15) patients, while the DF lung regions improved after high dose radiation in 85% of patients (13/15). Dose response differed among lung regions of FL, PF and DF (Figure-1 for all patients, Figure-2 for example).. A great individual difference on dose response relationship was seen cross all patients of DF regions. Overall functional changes at 3 months was significantly associated with long-term grade 1 radiation-induced-lung-toxicity by 24 months ( $P=0.02$ ).

**Conclusions:** Lung regions with various function at baseline change differently after radiation in patients with NSCLC. This is interesting, deserves further study.

Supported in part by NIH grants ASCO CDA, R21CA127057 and P01CA59827